Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00958724
Other study ID # 3144A2-1118 / B1891002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 2009
Est. completion date April 2010

Study information

Verified date April 2018
Source Puma Biotechnology, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs, as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors in Japanese patients.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date April 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Confirmed pathologic diagnosis of a solid tumor that is not curable with available therapies for which neratinib plus vinorelbine is a reasonable treatment option.

- At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors.

- Eastern Cooperative Oncology Group performance status of 0 to 2 (not declining within 2 weeks before signing the informed consent form).

- Recovery from all clinically significant AEs related to prior therapies (excluding alopecia).

- Left ventricular ejection fraction within the study site's limits of normal.

- Screening laboratory values within the following parameters:

- Absolute neutrophil count: 1.5 × 109/L

- Platelet count: 100 × 109/L

- Hemoglobin: 9.0 g/dL

- Serum creatinine: 1.5 × upper limit of normal

- Total bilirubin: 1.5 × ULN

- Aspartate aminotransferase and alanine aminotransferase: 2.5 × ULN (<= 5 × ULN if liver metastases are present).

- For women of childbearing potential, a negative urine or serum pregnancy test result before study entry.

- All female and male subjects who are biologically capable of having children must agree and commit to the use of a reliable method of birth control for the duration of the study and for 28 days after the last dose of test article. A subject is biologically capable of having children if he or she is using contraceptives or if his or her sexual partner is sterile or using contraceptives.

Exclusion Criteria:

- Prior treatment with anthracyclines with a cumulative dose of doxorubicin of >400 mg/m^2, or of epirubicin >800 mg/m^2, or the equivalent dose for other anthracyclines or derivatives.

- Major surgery, chemotherapy, radical (curative intent) radiotherapy, investigational agents, or other cancer therapy within at least 2 weeks before treatment day 1.

- Bone as the only site of disease.

- Active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth. (Subjects with a history of CNS metastases or cord compression are allowable if they have been definitively treated and are off anticonvulsants and steroids for at least 4 weeks before cycle 1 day 1) .

- QT (QTc) interval > 0.47 s or a known history of QTc prolongation or Torsades de Pointes.

- Presence of clinically significant or uncontrolled cardiac disease, including congestive heart failure (New York Heart Association functional classification of =2), angina requiring treatment, myocardial infarction within the past 12 months, or any clinically significant supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention.

- Pregnant or breastfeeding women. Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn disease, malabsorption, or grade 2 diarrhea of any etiology at baseline).

- Inability or unwillingness to swallow tablets (neratinib).

- Preexisting grade 2 or greater motor or sensory neuropathy.

- Subject known to be human immunodeficiency virus seropositive and/or have acute or chronic hepatitis B infection (hepatitis B surface antigen [HBsAg] positive) or hepatitis C infection (anti-HCV positive).

- History of known hypersensitivity to vinorelbine and any of its components.

- Any other cancer within 5 years prior to screening with the exception of contralateral breast carcinoma, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin.

- Clinically significant ongoing or recent infection within 2 weeks before treatment day 1.

- Evidence of significant medical illness or abnormal laboratory finding that would, in the investigator's judgment, make the subject inappropriate for this study. Examples include, but are not limited to, serious active infection (ie, requiring intravenous antibiotic or antiviral agent) or uncontrolled major seizure.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Neratinib

Vinorelbine


Locations

Country Name City State
Japan Shizuoka Cancer Center Shizuoka
Japan The Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo

Sponsors (1)

Lead Sponsor Collaborator
Puma Biotechnology, Inc.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose Limiting Toxicity (DLT) Number of participants experiencing DLT of neratinib in combination with vinorelbine in Japanese patients. From first dose date to 21st day
Secondary Best Overall Response Best Overall Response in Evaluable Population per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. From first dose date to progression or last tumor assessment, up to 40 weeks.
Secondary Duration of Objective Response The duration of objective response was measured from the time at which measurement criteria were met for Complete Response (CR) or Partial Response (PR) (whichever status was recorded first) until the first date on which recurrence or Progressive Disease (PD) was objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started. From first response date to PD/death, up to 40 weeks.
Secondary Objective Response Rate (ORR) Proportion of subjects who achieved complete response or partial response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. From first dose date to progression or last tumor assessment, up to 40 weeks.
Secondary Progression Free Survival Number of weeks between the date of the first dose of test article and the first date of disease recurrence or progression, or death due to any cause, was documented, censored at the last evaluation, investigator assessment.
Disease Progression (PD) is defined using Response Evaluation Criteria in Solid Tumors Criteria (v1.0), at least a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as reference the nadir LD, meaning the smallest sum of the LDs recorded since the treatment started; or unequivocal progression of existing nontarget lesions; or the appearance of any new lesions.
From first dose to last evaluation, up to 40 weeks.
Secondary Area Under the Curve (AUC) Tau AUC of Neratinib at day 8 following administration of Neratinib 240 mg in combination with Vinorelbine 25 mg/m^2 to Japanese Subjects with Cancer. Predose, and hour 1, 2, 4, 6, 8 and 24 on day 8.
Secondary Terminal-phase Elimination Half-life Terminal-phase elimination half-life of Neratinib at day 8 following Administration of Neratinib 240 mg in combination with Vinorelbine 25 mg/m^2 to Japanese Subjects with Cancer. Predose, and hour 1, 2, 4, 6, 8 and 24 on day 8.
See also
  Status Clinical Trial Phase
Completed NCT00728468 - A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients Phase 1
Completed NCT00445458 - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer Phase 1/Phase 2
Completed NCT00768469 - Study Evaluating Safety And Tolerability, Solid Tumor Phase 1
Recruiting NCT04226066 - Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT04908046 - A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06464055 - A Study of GQ1010 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06231550 - A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors Phase 1
Not yet recruiting NCT05383703 - Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor Phase 1
Recruiting NCT05773937 - A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors Phase 1
Completed NCT04328506 - Bioequivalency Study of CM082 Tablet in Healthy Volunteers Phase 1
Recruiting NCT05886374 - A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors Phase 1
Not yet recruiting NCT05949775 - Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors N/A
Terminated NCT02045095 - A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors Phase 1
Completed NCT00884845 - Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT05277454 - Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT Phase 1
Active, not recruiting NCT03792958 - Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors Phase 1
Withdrawn NCT00997360 - Study of PKI-179 Administered Orally to Subjects With Solid Tumors Phase 1
Completed NCT04126668 - A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers Phase 1
Recruiting NCT05338957 - A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. Phase 1/Phase 2
Recruiting NCT03047811 - The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors N/A